AKAN

Company Overview — What Does AKANDA CORP. Do?

Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products in the United Kingdom, Lesotho, and internationally. It intends to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers; and imports and sells medical cannabis-based products in the United Kingdom. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom. AKANDA CORP. (AKAN) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Tejinder Virk and employs approximately 110 people. With a market capitalization of $2M, AKAN is one of the notable companies in the Healthcare sector.

AKANDA CORP. (AKAN) Stock Rating — Reduce (April 2026)

As of April 2026, AKANDA CORP. receives a Reduce rating with a composite score of 34.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.AKAN ranks #3,731 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, AKANDA CORP. ranks #624 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AKAN Stock Price and 52-Week Range

AKANDA CORP. (AKAN) currently trades at $0.64. The stock lost $0.02 (3.6%) in the most recent trading session. The 52-week high for AKAN is $9.29, which means the stock is currently trading -93.1% from its annual peak. The 52-week low is $0.42, putting the stock 53.8% above its annual trough. Recent trading volume was 91K shares, suggesting relatively thin trading activity.

Is AKAN Overvalued or Undervalued? — Valuation Analysis

AKANDA CORP. (AKAN) carries a value factor score of 22/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.40x, versus the sector average of 2.75x. The price-to-sales ratio is 0.51x, compared to 1.66x for the average Healthcare stock.

At current multiples, AKANDA CORP. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

AKANDA CORP. Profitability — ROE, Margins, and Quality Score

AKANDA CORP. (AKAN) earns a quality factor score of 29/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -383.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -207.0% versus the sector average of -33.1%.

On a margin basis, AKANDA CORP. reports gross margins of 24.9%, compared to 71.5% for the sector. The operating margin is -523.8% (sector: -66.1%). Net profit margin stands at -489.6%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AKAN Debt, Balance Sheet, and Financial Health

AKANDA CORP. has a debt-to-equity ratio of 8.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $352,814. Cash and equivalents stand at $4M.

AKAN has a beta of 1.05, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for AKANDA CORP. is 17/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

AKANDA CORP. Revenue and Earnings History — Quarterly Trend

In TTM 2026, AKANDA CORP. reported revenue of $836,664. Net income for the quarter was $-4M. Gross margin was 24.9%. Operating income came in at $-4M.

In FY 2024, AKANDA CORP. reported revenue of $836,664. Net income for the quarter was $-4M. Gross margin was 24.9%. Revenue grew 97.5% year-over-year compared to FY 2023. Operating income came in at $-4M.

In FY 2023, AKANDA CORP. reported revenue of $423,683 and earnings per share (EPS) of $-639.03. Net income for the quarter was $-32M. Gross margin was 14.0%. Revenue grew -83.8% year-over-year compared to FY 2022. Operating income came in at $-4M.

In FY 2022, AKANDA CORP. reported revenue of $3M. Net income for the quarter was $-12M. Gross margin was 124.8%. Revenue grew 7105.2% year-over-year compared to FY 2021. Operating income came in at $-18M.

Over the past 6 quarters, AKANDA CORP. has demonstrated a growth trajectory, with revenue expanding from $571 to $836,664. Investors analyzing AKAN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AKAN Dividend Yield and Income Analysis

AKANDA CORP. (AKAN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AKAN Momentum and Technical Analysis Profile

AKANDA CORP. (AKAN) has a momentum factor score of 41/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 53/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 56/100 reflects moderate short selling activity.

AKAN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, AKANDA CORP. (AKAN) ranks #624 out of 838 stocks based on the Blank Capital composite score. This places AKAN in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AKAN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AKAN vs S&P 500 (SPY) comparison to assess how AKANDA CORP. stacks up against the broader market across all factor dimensions.

AKAN Next Earnings Date

No upcoming earnings date has been announced for AKANDA CORP. (AKAN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AKAN? — Investment Thesis Summary

The quantitative profile for AKANDA CORP. suggests caution. The quality score of 29/100 flags below-average profitability. The value score of 22/100 indicates premium valuation. High volatility (stability score 17/100) increases portfolio risk.

In summary, AKANDA CORP. (AKAN) earns a Reduce rating with a composite score of 34.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AKAN stock.

Related Resources for AKAN Investors

Explore more research and tools: AKAN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AKAN head-to-head with peers: AKAN vs AZN, AKAN vs SLGL, AKAN vs VMD.